DOJ orders Evoqua to pay $8.5M over admitted securities fraud
By 
Jeff Dale2024-05-16T18:52:00
Evoqua Water Technologies agreed to pay $8.5 million as part of a nonprosecution agreement (NPA) with the Department of Justice (DOJ) to settle admitted criminal charges related to fraudulent revenue recognition.
Evoqua, which designs industrial wastewater treatment and filtration plants, was headquartered in Pennsylvania. Its aquatics and disinfection (A&D) division was based in Rhode Island, where the misconduct took place, the DOJ said in a press release Tuesday.
In March 2023, the company settled its civil liabilities related to the same misconduct with the Securities and Exchange Commission (SEC) by agreeing to pay a separate $8.5 million penalty. Evoqua also paid nearly $16.7 million to settle a shareholder class-action lawsuit over the same misconduct.
Related articles
-
News BriefChina-based Cloopen Group avoids fine in SEC accounting fraud case
China-based technology company Cloopen Group Holding won’t pay a fine in settling with the Securities and Exchange Commission over an alleged accounting fraud scheme perpetrated by two of its former senior managers.
-
News BriefCantaloupe fined $1.5M in SEC accounting fraud case
Electronic payments software company Cantaloupe agreed to pay a $1.5 million penalty to settle allegations of accounting fraud levied by the Securities and Exchange Commission arising from improper revenue recognition practices.
-
News Brief
Evoqua Water Technologies to pay $8.5M for alleged revenue inflation
Evoqua Water Technologies Corp. agreed to pay $8.5 million to resolve charges the actions of a former company finance director led the firm to misstate its revenue in filings with the Securities and Exchange Commission.
More from Regulatory Enforcement
-
News BriefCFPB ends probe into Meta’s financial advertising practices
Meta says it is no longer under investigation by the U.S. Consumer Financial Protection Bureau (CFPB), the latest instance of the agency scaling back enforcement under President Donald Trump.
-
News BriefTexas sues Johnson & Johnson, Kenvue over alleged misleading marketing of Tylenol
Texas Attorney General Ken Paxton sued two pharmaceutical companies for ”deceptively marketing Tylenol to pregnant mothers” despite risks linked to autism. The filing came two days before HHS Secretary Robert F. Kennedy Jr. appeared to walk back the claims.
-
News BriefCFPB scraps bad-actor registry, citing cost-benefit issues
The Consumer Financial Protection Bureau shut down a registry of non-bank financial firms that broke consumer laws. The agency cites the costs being ”not justified by the speculative and unquantified benefits to consumers.”